Table 6.
Meta-analysis results of outcomes reported by studies comparing EVL or SRL vs. MMF a.
| Outcome | EVL (ld) vs. MMF | EVL (hd) vs. MMF | SRL vs. MMF | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Design (N) | Time (mo.) | Relative Risk b (95% CI) | Statistics c | Study Design (N) | Time (mo.) | Relative Risk b (95% CI) | Statistics c | Study Design (N) | Time (mo.) | Relative Risk b (95% CI) | Statistics c | ||||
| p | I2 | p | I2 | p | I2 | ||||||||||
| Total Infections | RCT [54,59] (946) | 12 | 0.62 (0.26, 1.48) | 0.28 | 92 | RCT [54,59] (946) | 12 | 0.83 (0.58, 1.18) | 0.29 | 70 | − | − | − | − | − |
| CMV infections | RCT [54,59] (946) | 12 | 0.23 (0.12, 0.42) | <0.01 | 0 | RCT [54,59] (946) | 12 | 0.15 (0.01, 2.17) | 0.16 | 73 | − | − | − | − | − |
| RCT [55,56] (781) | 36 | 0.47 (0.16, 1.41) | 0.18 | 78 | RCT [55,56] (780) | 36 | 0.47 (0.29, 0.74) | <0.01 | 0 | ||||||
| Anemia | RCT [54,59] (946) | 12 | 0.97 (0.79, 1.20) | 0.80 | 0 | RCT [54,59] (946) | 12 | 1.15 (0.95, 1.40) | 0.15 | 0 | − | − | − | − | − |
| RCT [55,56] (781) | 36 | 1.17 (0.73, 1.88) | 0.50 | 76 | RCT [55,56] (780) | 36 | 1.47 (0.97, 2.23) | 0.07 | 74 | ||||||
| Leukopenia | RCT [55,56] (781) | 36 | 0.50 (0.24, 1.06) | 0.07 | 42 | − | − | − | − | − | − | − | − | − | − |
| Dyslipidemia | RCT [54,59] (946) | 12 | 1.68 (1.01, 2.79) | 0.05 | 68 | RCT [54,59] (946) | 12 | 1.63 (1.08, 2.46) | 0.02 | 52 | − | − | − | − | − |
| Hypertension | RCT [54,59] (946) | 12 | 0.98 (0.73, 1.32) | 0.87 | 0 | RCT [54,59] (946) | 12 | 0.97 (0.80, 1.18) | 0.78 | 0 | − | − | − | − | − |
| Lymphoceles | RCT [55,56] (781) | 36 | 1.54 (0.96, 2.45) | 0.07 | 14 | RCT [55,56] (780) | 36 | 2.08 (1.00, 4.32) | 0.05 | 63 | − | − | − | − | − |
| Withdraw | RCT [55,56] (781) | 36 | 1.23 (1.07, 1.43) | 0.005 | 0 | RCT [55,56] (780) | 36 | 1.41 (1.23, 1.62) | <0.01 | 0 | RCT [57,58] (459) | 12 | 1.81 (1.20, 2.72) | 0.004 | 0 |
Abbreviations: (ld), Low dose; (hd), High dose; mo., months. a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with TOR-I. c p: p-value for relative risk estimation; I2: test for heterogeneity.